AdvisorShares Investments LLC Acquires 180,229 Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

AdvisorShares Investments LLC boosted its holdings in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 138.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 310,314 shares of the company’s stock after acquiring an additional 180,229 shares during the period. AdvisorShares Investments LLC owned 1.98% of NRx Pharmaceuticals worth $683,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals during the fourth quarter worth approximately $33,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Trading Up 1.4 %

NRXP stock opened at $2.10 on Tuesday. NRx Pharmaceuticals, Inc. has a 1-year low of $1.10 and a 1-year high of $6.01. The stock has a 50-day moving average price of $2.05 and a 200-day moving average price of $2.09. The firm has a market cap of $35.52 million, a PE ratio of -0.98 and a beta of 1.41.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts forecast that NRx Pharmaceuticals, Inc. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, March 31st. BTIG Research started coverage on shares of NRx Pharmaceuticals in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $18.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $28.25.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.